Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Cell Cycle Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CCNA2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CCNA2 Recombinant Protein (WT & Custom Mutants) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Ideal for PROTAC / PPI assays. |
View CCNA2 Products |
| Complex | Cyclin A2/CDK2 Complex Active kinase complex for screening. HEK293 Expressed. |
View CCNA2 Products |
| Gene Delivery | CCNA2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View CCNA2 Products |
| Benchmark Ab | Anti-CCNA2 Control Antibody Recombinant positive control for western blot and target engagement assays. |
View CCNA2 Products |
| Validator | CCNA2 siRNA Set For knockdown verification and synthetic lethality screens. |
View CCNA2 Products |
| Related Target A | CDK2 Crucial kinase partner; CCNA2-CDK2 complex is the primary functional unit in the S-phase. |
View CDK2 Products |
| Related Target B | CDK1 Alternative kinase partner driving the G2/M transition. |
View CDK1 Products |
| Related Target C | Cyclin E1 (CCNE1) Compensatory G1/S cyclin; critical for resistance bypass studies. |
View CCNE1 Products |
| Related Target D | Cyclin B1 (CCNB1) Mitotic cyclin homolog; required for selectivity counter-screening. |
View CCNB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular Protein Binding Validation | High Purity (>95%), Theoretical MW Sequence Verified proteins optimized for SPR and TR-FRET. |
| Protein-Protein Interaction (PPI) Disruption | Standardized formulation supporting structural assays for CCNA2-CDK2 interface inhibitors. |
| Target Degradation (PROTACs) | HEK293 Expressed (Native Post-Translational Modifications) to ensure accurate ubiquitination topology. |
| Cyclin-CDK Complex Integrity | Premade Cyclin A2/CDK2 Heterodimer Complex; Sequence Verified; >95% purity by SDS-PAGE. |
| Resistance Mutation Profiling | Mutant CCNA2 Variants Available (Custom); High Purity for SPR/BLI binding studies. |
| Specificity vs CCNE1/CDK2 | Paralog Panel: CCNA2, CCNE1, CCNB1 available for counter-screening. |
| False Positives in Screening | Validated siRNA included for absolute target specificity checks. |
Live CCNA2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Cyclin A2 (CCNA2) therapeutics is intensifying, with major players shifting focus from traditional non-selective kinase inhibitors to highly specific PROTACs, molecular glues, and precise Protein-Protein Interaction (PPI) inhibitors. As a core regulatory subunit lacking intrinsic enzymatic activity, directly targeting CCNA2 requires advanced modalities. As first-generation CDK therapies reach the clinic, the next wave of R&D is targeting the direct degradation of CCNA2 to overcome CDK-inhibitor resistance mechanisms in solid tumors. Key resistance mechanisms include CCNA2-CDK2 pathway compensatory activation and CCNE1 amplification, driving interest in selective CDK2-CCNA2 complex disruptors and synthetic lethal combinations.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Selective CDK2 Inhibitor) | Pfizer, Bayer, Blueprint Medicines | Ovarian, Breast, CCNE1-amplified cancers, RB1-deficient tumors | Kinase Activity Assay (Need active Cyclin A2/CDK2 complex) |
| PROTAC / Degrader | Arvinas, Nurix, C4 Therapeutics | Refractory Solid Tumors | Ternary Complex Formation (Need high-purity native CCNA2 and CDK2) |
| Molecular Glue | Monte Rosa, Orionis | Oncology | PPI Disruption Assay (Need WT and Mutant CCNA2) |
| PPI Inhibitor (Peptide/Stapled Peptide) | Academic / Early Biotech | Breast Cancer, Hepatocellular Carcinoma | Affinity Assay (Need structurally intact CCNA2 to map CDK2 binding face) |
| siRNA / RNAi | Alnylam, Arrowhead (Analogous pathways) | Liver Cancer | Knockdown Validation (Need Sequence Verified mRNA/siRNA tools) |
| Synthetic Lethality / Combo | Oncology Biotech Consortiums | HR-proficient / CCNE1-amp Tumors | Cell Line Engineering (Need CCNA2 ORF lentivirus and siRNA for isogenic pairs) |
Key Mutations and Variants
- rs769242 (dbSNP): A documented variant in CCNA2 (UniProt P20248 VAR_018819). While its functional impact in drug resistance is not fully characterized, it represents a potential site for mutation profiling in resistance studies. TarMart offers custom mutant CCNA2 recombinant proteins for such investigations.